

Corrected Copy

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p style="text-align: center;">Licensee</p> <p>1. Munson Healthcare Cadillac Hospital</p> <p>2. 400 Hobart Street Cadillac, MI 49601</p>	<p>In accordance with letter dated December 15, 2014,</p> <p>3. License number 21-10717-01 is amended in its entirety to read as follows:</p> <hr/> <p>4. Expiration date June 30, 2021</p> <hr/> <p>5. Docket No. 030-02088 Reference No.</p>
---	--

- | | | |
|---|--|---|
| <p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Iodine-125 permitted by 10 CFR 35.400</p> <p>D. Palladium-103 permitted by 10 CFR 35.400</p> | <p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p> <p>C. Sealed sources (Bard Brachytherapy, Inc. Model STM 1251)</p> <p>D. Sealed sources (Theragenics Corporation Model TheraSeed® 200)</p> | <p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As needed</p> <p>B. As needed</p> <p>C. 800 millicuries</p> <p>D. 800 millicuries</p> |
|---|--|---|

9. Authorized use:
- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
- B. Any imaging and localization study permitted by 10 CFR 35.200.
- C. and D. Any manual brachytherapy procedure permitted by 10 CFR 35.400.

CONDITIONS

10. Licensed material may be used or stored only at the licensee's facilities located at 400 Hobart Street, Cadillac, Michigan.
11. The Radiation Safety Officer (RSO) for this license is Steven Klegman, D.O.
12. Licensed material is only authorized for use by, or under the supervision of:
- A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number

21-10717-01

Docket or Reference Number

030-02088

Amendment No. 23

Corrected Copy

B. The following individuals are authorized users for medical use as indicated:

Authorized UsersMaterial and Use

Richard M. Cover, M.D.	10 CFR 35.100 and 35.200.
Clark D. Phelps, Jr., M.D.	10 CFR 35.100 and 35.200.
Todd C. Space, M.D.	10 CFR 35.100 and 35.200.
Charles J. Weitz, M.D.	10 CFR 35.100 and 35.200.
C. Paul Williams, M.D.	10 CFR 35.100 and 35.200.
Michelle Lung, M.D.	10 CFR 35.100 and 35.200.
Fredrick Brodeur, M.D.	10 CFR 35.100 and 35.200.
Steven Klegman, D.O.	10 CFR 35.100 and 35.200.
Deborah Jean Crowe, M.D.	10 CFR 35.100 and 35.200.
Paul Williams, M.D.	10 CFR 35.100 and 35.200.
Daniel Dall'Olmo, M.D.	10 CFR 35.100 and 35.200.
Linnea J. Priest, M.D.	10 CFR 35.100 and 35.200.
David J. Steffey, M.D.	10 CFR 35.100 and 35.200.
Todd Wilson, M.D.	10 CFR 35.100 and 35.200.
Stephen C. Hodges, M.D.	10 CFR 35.100 and 35.200.
Michael D. Aja, M.D.	10 CFR 35.400.
Robert M. Prust, M.D.	10 CFR 35.400.
David Keith Heimbürger, M.D.	10 CFR 35.400.
Doug Brown, M.D.	10 CFR 35.400.
Rhonda Lee VanDerVeen, D.O.	10 CFR 35.100 and 35.200.
Lafayette Richmond, M.D.	10 CFR 35.100 and 35.200.
Ryan Holmes, M.D.	10 CFR 35.100 and 35.200.
Thomas W. Crosby, M.D.	10 CFR 35.200.

13. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
21-10717-01Docket or Reference Number
030-02088Amendment No. 23
Corrected Copy

14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated March 11, 2011; and
- B. Letters dated May 18, 2011 and **December 15, 2014**; and
- C. Letter received **April 9, 2015**.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date APR 20 2015

By

Sara A. Forster, M.S.
Materials Licensing Branch
Region III